In collaboration with 
 

Title: A Rash of Developments in Chronic Spontaneous Urticaria Treatment and Management

Program Description
Chronic spontaneous urticaria (CSU), which affects upwards of 1% of the general population, is an increasingly prevalent and debilitating mast-cell mediated disease that can prove challenging to treat adequately. Although CSU sometimes resolves spontaneously after 2 to 5 years, upwards of 50% of patients have moderate to severe disease activity and experience recurring episodes of hives with or without angioedema in excess of 5 years. Because discomforting, dermatologic symptoms tend to manifest more forcefully at night, CSU impairs sleep and over time leads to fatigue, irritability, reduced productivity, anxiety, and depression. This educational curriculum establishes meaningful, small group interactions that will, through a variety of collaborative educational experiences, help allergy and dermatology clinicians identify and address longstanding gaps in care and be better positioned to optimize patient outcomes.

Intended Audiences
This educational initiative is specifically intended for allergists, dermatologists, allergy and dermatology nurse practitioners and physician assistants responsible for the diagnosis, treatment, and long-term management of patients with chronic spontaneous urticaria.

Commercial Supporters
This activity is supported by an educational grant from Novartis.

Educational Objectives
After taking part in this educational activity, clinicians should become better able to:

• Identify the diagnostic challenges and delays associated with CSU
• Describe the underlying pathophysiology of CSU, with a focus on type I and type II autoimmune mechanisms
• Discuss the mechanism of action, efficacy, and safety profiles of novel treatments for CSU, namely Bruton’s tyrosine kinase (BTK) inhibitors
• Explore strategies to improve coordination among specialists and supporting advanced practice providers to ensure appropriate de-escalation of treatment

Accredited Provider & Accreditation Statements
This activity is accredited through AAAAI. 

CME: The American Academy of Allergy Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CE: The American Academy of Allergy Asthma and Immunology (AAAAI) is a Provider approved by the California Board of Registered Nursing, Provider #10704.

Credit Designation Statement
The AAAAI designates this activity for up to 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accredited Provider Disclosure 
None of the planners, reviewers, and AAAAI / GatherEd staff for this educational activity have relevant financial relationship(s) with ineligible companies to disclose.

Faculty

Dr. Jonathan Bernstein Partner, Bernstein Allergy Group, Inc. Professor of Medicine, Division of Allergy & Immunology University of Cincinnati

Disclosures:

Novartis (Ongoing): Consultant: Urticaria (also speaker and PI) - promotional speaking concluded 3/2022 Amgen (Ongoing): Research Grant: CSU and asthma - funds go to institution TSLP antagonist  Astra Zeneca (Ongoing): Research Grant: Asthma, CSU grants - funds for grants go to institution; also a consultant; promotional speaking ended 3/2/2022 TEVA (Ongoing): Research Grant: Asthma and CSU medications - funds go to institution

	Brian S. Kim, MD Vice Chair of Research, Department of Dermatology Icahn School of Medicine, Mount Sinai
Disclosures:	No relevant financial disclosures.

Technical Writer
Thomas Mitchell

Disclosures: 
No relevant financial disclosures.

Disclosure of Financial Relationships Policy
AAAAI adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME/CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Disclosure of Unlabeled Use
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a clinician relative to diagnostic and treatment options for a specific patient's medical condition.

Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AAAAI, RealCME, or GatherEd. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the accreditation of this activity, please contact cme@aaaai.org

Method of Participation/Instructions
Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-assessment and evaluation, and have received a digital copy of your credit certificate.

In order to claim the maximum amount of credit available, you must complete all of the following:

• Baseline/Final Assessments: 30 minutes each for a total of 1.0 hour of CME
• Three Self Study Modules (3) - 15-20 minutes each for a total of 0.75 hour of CME
• Two Live Group Discussions (2) - 30-45 minutes each for a total of 1.50 hours of CME
• Three Group Challenges (3) -30 minutes each for a total of 1.50 hours of CME
  (Group Challenge also includes developing Action Plan)